MedX is a very undervalued company. They have 2 product lines a therapeutic laser line and that business has been growing very well since they revamped the whole product line. I expect revenue of 1.5-2 million from this line over this calendar year. The second product line which is the SIAscopy business this is such a gamechanger product. They sell the units to pharmacies/med clinics and make a healthy margin but they also receive approximately 10 per scan. In Norway, they have over 104 locations in Boots pharmacies and have done over 77,000 scans and captured 862 melanomas. I believe with their new telemedicine portal and the new channel partners they could easily have over 1,500 locations deployed over the next 12 months. If that happens along with the laser sales MedX will be wildly profitable. They have a large tax loss carry forward so this means the net revenue goes straight to the bottom line.This stock has a lot left in it in my opinion.
S
Empower and medx just a pilot program in 2 clinics. If successful then depending on the roll out as a result, might see further push up. Been holding on to this since 11 cents.
B
Only 1500 shares traded today. No updates from management. No activity on this message board. Does anybody have any news or knowledge about this company?
D
15c coming soon
C
This stock seems to be on the move today, does anyone know if there is any news...
G
MISSISSAUGA, Ontario--(BUSINESS WIRE)--
MedX Health Corp. (“MedX”) (MDX.V) announced today that it is launching DermSecure™, its telemedicine platform, in six Ontario clinics. MedX will begin rolling out DermSecure™ across Ontario and subsequently Canada while finalizing its introduction into a number of international markets. It is currently working on a DermSecure™ roll-out with its Spanish distribution partner as well as plans for the US, Mexico, and the Netherlands. MedX’s DermSecure™ has been built to the leading data repository standards to allow for integration with Electronic Medical Record (EMR’s) systems. Its development roadmap includes the addition of features and functions to the DermSecure™ platform that will be released on a regular basis.
“DermSecure™ is a secure telemedicine platform, coupled with MedX’s innovative imaging technology, SIAscopy, that will provide dermatologists and patients access to the most advanced mole and lesion rapid assessment system available in the marketplace. This technology will be deployed in medical clinics to provide MedX’s non-invasive skin scanning technology to physicians who will be able to have a dermatologist assess their patients’ suspicious moles or lesions remotely,” said Scott Spearn, President of MedX. “DermSecure™ clearly offers great benefits to patients and primary care physicians by working with dermatologists, leveraging their skills. DermSecure™ is a Software-as-a-Service revenue model, with recurring revenue growth – a key development for MedX,” noted Mr. Spearn.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the success of the Company’s sales strategies.
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed an agreement with Richmar, a Compass Health Brands Company, to manufacture and su
MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed an agreement with Richmar, a Compass Health Brands Company, to manufacture and su
www.businesswire.com
M
It is shocking folks are not jumping on the MDX train ......Great company like it all the way to a loonie
J
I am not sure what is going on with MDX, doesn't seem to be any news. There was a promising outlook, and then crickets. "the longer the base, the better the case"?!? If the company does not start speaking to their shareholders, I think I will simply move on.
i
Solid news today, will be launching an easy-access skin scanning/assessment program in the Netherlands; if you're interested in the best new plays from across the Canadian markets check out SmallCapCanada, they consistently uncover the companies that are showing strong signs of growth and deliver quality reports that are packed with insightful info and market analysis- just a great resource for any investor- SmallCapCanada
A
I want to see .30 this week. Let’s keep moving in the right direction!
A
No news till earnings I guess August 22
T
Beacon Securities starts coverage on the melanoma equipment detection company with a "buy" and a price target of $0.45 (Canadian), which projects a 350% gain. Beacon has not provided investment banking services to MDX within the last 12 months.
The second product line which is the SIAscopy business this is such a gamechanger product. They sell the units to pharmacies/med clinics and make a healthy margin but they also receive approximately 10 per scan. In Norway, they have over 104 locations in Boots pharmacies and have done over 77,000 scans and captured 862 melanomas. I believe with their new telemedicine portal and the new channel partners they could easily have over 1,500 locations deployed over the next 12 months. If that happens along with the laser sales MedX will be wildly profitable. They have a large tax loss carry forward so this means the net revenue goes straight to the bottom line.This stock has a lot left in it in my opinion.
Been holding on to this since 11 cents.
MedX Health Corp. (“MedX”) (MDX.V) announced today that it is launching DermSecure™, its telemedicine platform, in six Ontario clinics. MedX will begin rolling out DermSecure™ across Ontario and subsequently Canada while finalizing its introduction into a number of international markets. It is currently working on a DermSecure™ roll-out with its Spanish distribution partner as well as plans for the US, Mexico, and the Netherlands. MedX’s DermSecure™ has been built to the leading data repository standards to allow for integration with Electronic Medical Record (EMR’s) systems. Its development roadmap includes the addition of features and functions to the DermSecure™ platform that will be released on a regular basis.
“DermSecure™ is a secure telemedicine platform, coupled with MedX’s innovative imaging technology, SIAscopy, that will provide dermatologists and patients access to the most advanced mole and lesion rapid assessment system available in the marketplace. This technology will be deployed in medical clinics to provide MedX’s non-invasive skin scanning technology to physicians who will be able to have a dermatologist assess their patients’ suspicious moles or lesions remotely,” said Scott Spearn, President of MedX. “DermSecure™ clearly offers great benefits to patients and primary care physicians by working with dermatologists, leveraging their skills. DermSecure™ is a Software-as-a-Service revenue model, with recurring revenue growth – a key development for MedX,” noted Mr. Spearn.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the success of the Company’s sales strategies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180904005830/en/
https://www.businesswire.com/news/home/20190304005242/en/MedX-Health-Corp.-Announces-Private-Label-Distributor